Display options
Cite
Kuroi K, Osaki A, Kawami H, et al. A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast Cancer. 1997;4(2):115-119doi: 10.1007/BF02967064.
Kuroi, K., Osaki, A., Kawami, H., Murakami, S., & Toge, T. (1997). A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast cancer (Tokyo, Japan), 4(2), 115-119. https://doi.org/10.1007/BF02967064
Kuroi, et al. "A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil." Breast cancer (Tokyo, Japan) vol. 4,2 (1997): 115-119. doi: https://doi.org/10.1007/BF02967064
Kuroi K, Osaki A, Kawami H, Murakami S, Toge T. A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast Cancer. 1997 Jul 31;4(2):115-119. doi: 10.1007/BF02967064. PMID: 11091585.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer. 1997 Jul 31;4(2):115-119. doi: 10.1007/BF02967064.

A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil.

Breast cancer (Tokyo, Japan)

Kuroi, Osaki, Kawami, Murakami, Toge

Affiliations

  1. Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan.

PMID: 11091585 DOI: 10.1007/BF02967064

Abstract

Thirty-two patients with advanced breast cancer refractory to combination chemotherapy with cyclophosphamide (CPA), doxorubicin (ADR) and 5-fluorouracil (5-EU) (CAF) were treated with the combination of mitomycin C, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy. Observed responses included 6 patients (18.7%) with complete response (CR) and 7 (21.9%) with partial response (PR). Two (50%) out of 4 patients who had bone pain due to bone metastasis noted pain relief. CR or PR were obtained in 4 out of 12 patients who had not responded to the previous CAF therapy. While grade III myelosuppression was observed in 3 patients, other adverse effects were minimal. It is suggested that this combination therapy may be recommended for advanced breast cancer patients as a second therapy.

Publication Types